| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Harvard Bioscience, Inc. (HBIO) has 8 insiders with recent SEC Form 4 filings, including 7 buys and 6 sells. HBIO is classified in the Health Care Equipment & Supplies industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 2.80M | $16.41M | - | |
| CEO | 180.0K | $1.06M | - | |
| Dir | 58.7K | $344.4K | - | |
| Dir | 48.6K | $285.0K | - | |
| CFO | 47.5K | $278.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2018 | Uveges George | Director | Sale+OE | 22,250 | $4.58 | $101,905.00 | -13.5% | |
| Mar 9, 2018 | Duchemin Jeffrey | Chief Executive Officer | Sell | 87,022 | $4.53 | $393,963.44 | -6.3% | |
| Mar 7, 2018 | Gagnon Robert E.67 | Chief Financial Officer | Sell | 97,087 | $4.62 | $448,541.94 | -21.3% | |
| Mar 7, 2018 | Uveges George | Director | Sell | 35,054 | $4.61 | $161,598.94 | -17.7% | |
| Jun 12, 2017 | Duchemin Jeffrey | Chief Executive Officer | Sell | 22,000 | $2.66 | $58,520.00 | -2.7% | |
| Jun 12, 2017 | Duchemin Jeffrey | Chief Executive Officer | Buy | 22,000 | $2.76 | $60,720.00 | +2.8% | |
| Jun 8, 2017 | Green James W70 | Director | Buy | 7,712 | $2.55 | $19,665.60 | +7.5% | |
| May 26, 2017 | Gagnon Robert E.67 | Chief Financial Officer | Buy | 1,000 | $2.33 | $2,330.00 | +0.2% | |
| May 25, 2017 | Lewis Earl R61 | Director | Buy | 12,238 | $2.35 | $28,764.54 | +1.3% | |
| May 24, 2017 | Lewis Earl R61 | Director | Buy | 10,000 | $2.38 | $23,800.00 | +1.2% |